Product Code: IRTNTR9324
About Migraines
A migraine is characterized by repeated attacks of a severe headache, nausea, vomiting, and extreme sensitivity to light and sound. Women are more prone to the disease compared to men owing to the fluctuating levels of hormones in their bodies. Therapeutic agents such as anti-inflammatory painkillers, antimigraine drugs, antisickness medicines, and triptans are used for the treatment of the disease.
Technavio's analysts forecast the global migraine drugs market to grow at a CAGR of 4.56% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global migraine drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that will be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.
The market is divided into the following segments based on geography:
Technavio's report, Global Migraine Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
- Allergan
- Endo International
- GlaxoSmithKline
- Impax
- Pfizer
Other Prominent Vendors
- Abbott
- Aegis Therapeutics
- Aeriel BioPharma
- Alder Biopharmaceuticals
- Amgen
- Astellas
- AstraZeneca
- Bayer
- CoLucid
- Dr. Reddy's Laboratories
- Eisai
- Eli Lilly
- Ethypharm
- IntelGenx
- Johnson & Johnson
- Klaria
- Kowa Pharmaceuticals America
- Luitpold Pharmaceuticals
- Meda
- Merck
- OptiNose
- Pfizer
- Pozen
- Raptor
- RedHill
- SUDA
- Teva
- TG Therapeutics
- NValeant
- Winston Pharmaceuticals
- Zogenix
Market driver
- Growing awareness about migraine and its treatment options
- For a full, detailed list, view our report
Market challenge
- Lack of proper diagnosis
- For a full, detailed list, view our report
Market trend
- Antimigraine devices and headbands
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
PART 05: Disease overview
- Types
- Cause
- Management
- Epidemiology
- Economic burden
- PART 06: Pipeline analysis
- Semprana
- Rizaport
- Sumatriptan
- DFN-11
- Lasmiditan
- SUD001
- AMG 334
- DFN-02
PART 07: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 08: Market segmentation by type of treatment
PART 09: Market segmentation by therapeutic class
- Triptans
- Ergot alkaloids
- Other
PART 10: Geographical segmentation
- Global migraine drugs market by geographical segmentation 2015-2020
- Migraine drugs market in Americas
- Migraine drugs market in EMEA
- Migraine drugs market in APAC
PART 11: Market drivers
- Growing awareness about migraine and its treatment options
- Tentative approval of pipeline candidates
- High unmet needs
- Increased prevalence of migraines
PART 12: Impact of drivers
PART 13: Market challenges
- Lack of proper diagnosis
- Adverse effects of drugs
- Increased preference for alternative therapies
- Generic penetration
PART 14: Impact of drivers and challenges
PART 15: Market trends
- Antimigraine devices and headbands
- Increase in R&D
- Novel product innovations
- Strategic alliances
PART 16: Vendor landscape
- Competitive scenario
- Allergan
- Endo International
- GlaxoSmithKline
- Impax
- Pfizer
- Other prominent vendors
PART 17: Appendix
PART 18: Explore Technavio
List of Exhibits
- Exhibit 01: Product offerings
- Exhibit 02: Percentage of migraine sufferers worldwide by gender
- Exhibit 03: Global migraine drugs market: Pipeline portfolio
- Exhibit 04: Global migraine drugs market 2015-2020 ($ billions)
- Exhibit 05: Five forces analysis
- Exhibit 06: Preventative medications based on efficacy of drugs
- Exhibit 07: Medications used based on severity of migraines
- Exhibit 08: Percentage share of preventative and abortive migraine medications in US 2015
- Exhibit 09: Segmentation of global migraine drugs market by therapeutic class 2015
- Exhibit 10: Market share of triptans by ROA 2015
- Exhibit 11: Global migraine drugs market by geography 2015
- Exhibit 12: Global migraine drugs market by geography 2015-2020 ($ millions)
- Exhibit 13: Migraine drugs market in Americas 2015-2020 ($ billions)
- Exhibit 14: Migraine drugs market in EMEA 2015-2020 ($ millions)
- Exhibit 15: Migraine drugs market in APAC 2015-2020 ($ millions)
- Exhibit 16: Impact of drivers
- Exhibit 17: Percentage of population diagnosed with migraine in US 2014
- Exhibit 18: Impact of drivers and challenges
- Exhibit 19: Allergan: YoY growth rate and revenue of Botox 2012-2014 ($ millions)
- Exhibit 20: Allergan: Key takeaways
- Exhibit 21: Endo International: Key takeaways
- Exhibit 22: GlaxoSmithKline: YoY growth rate and revenue of Imigran/Imitrex 2012-2014 ($ millions)
- Exhibit 23: GlaxoSmithKline: Key takeaways
- Exhibit 24: Impax: YoY growth rate and revenue of Zomig in the US 2012-2014 ($ millions)
- Exhibit 25: Impax: Key takeaways
- Exhibit 26: Pfizer: YoY growth rate and revenue of Relpax 2012-2014 ($ millions)
- Exhibit 27: Pfizer: Key takeaways
